Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

March 9, 2018: By Joan McKenna

Imprimis Pharmaceuticals Inc. announced March 8 that its 2017 revenues totaled $26.77 million, a 34 percent increase over 2016 revenues of $19.94 million.

Fourth quarter revenues totaled $7.34 million, an increase of 27 percent over the 2016 total of $5.79 million.

The San Diego-based compounder said its average order at its 503B outsourcing facility in New Jersey was $1,400 in the fourth quarter.

Mark Baum, CEO of Imprimis, said Q4-2017 was the 15th consecutive quarter of double-digit or better year-over-year growth. The company’s customer network now exceeds 2 thousand prescribers, and it expects four new ophthalmic formulations to become available from its 503B facility during Q1-2018.

Imprimis attributed its annual revenue increase to a rise in sales and added ophthalmic formulations.

The company, which began generating revenues in 2014, has been attempting to disrupt the market with lower prices.

Imprimis said net losses for 2017 totaled $11.99 million. Its debt totaled $88.84 million at the end of 2017, and it expects to incur further losses as it continues to grow.

The company said it has raised more than $55 million through equity and debt financings since January 2015.

Addressing Supply Chain Vulnerabilities

On March 6, Imprimis announced that it has launched a new program to provide ophthalmologists and optometrists with custom compounded ophthalmic medications that are increasingly difficult to find, with products shipping within 24 to 48 hours.  Imprimis intends to make this program available in all 50 US states.

The move followed a Jan. 30 hearing by a US House subcommittee in which George Williams, MD, the AAO’s incoming president and a practicing retinal specialist in Michigan, testified that current FDA enforcement policies of state-regulated pharmacies is forcing practitioners to rely solely on outsourcing facilities, and sometimes only one facility, for office-use drugs, creating supply chain vulnerabilities.


Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023